卡马西平治疗新诊断部分性癫痫的临床效果及对认知功能的影响

Clinical Effect of Carbamazepine in the Treatment of Newly Diagnosed Partial Epilepsy and its Influence on Cognitive Function

目的 探讨新诊断部分性癫痫患者采用卡马西平(CBZ)治疗的临床效果及对认知功能的影响。方法 选取2020年3月至2022年9月于鹿邑县人民医院接受治疗的新诊断部分性癫痫患者共计136例,以随机数字表法分为研究组(n=68)与对照组(n=68),对照组给予托吡酯片治疗,研究组给予CBZ联合托吡酯片治疗,对两组临床疗效、认知功能、生存质量、血清指标、不良反应进行比较。结果 研究组治疗有效率(95.59%)较对照组(80.88%)更高,差异具有统计学意义(P <0.05);两组治疗3个月后蒙特利尔认知评估量表(MoCA)评分提高,且研究组较对照组更高,差异均有统计学意义(P <0.05);两组治疗后癫痫患者生活质量评定量表-31(QOLIE-31)提高,且研究组较对照组更高,差异均有统计学意义(P <0.05);两组治疗后血清神经肽Y(NPY)、胶质纤维酸性蛋白(GFAP)水平降低,且研究组较对照组更低,差异均有统计学意义(P <0.05);研究组不良反应发生率(4.41%)较对照组(20.59%)更低,差异具有统计学意义(P <0.05)。结论 新诊断部分性癫痫给予CBZ治疗能够提升临床疗效,增强认知功能,提高生活质量,改善血清指标,减少不良反应发生。

Objective To explore the clinical effect of carbamazepine(CBZ) treatment and its influence on cognitive function in patients with newly diagnosed partial epilepsy.Methods A total of 136 patients with newly diagnosed partial epilepsy who were treated in our hospital from March 2020 to September 2022 were selected.They were randomly divided into the study group(n=68) and the control group(n=68).The control group was treated with topiramate tablets,and the research group was treated with CBZ combined with topiramate tablets.The clinical efficacy,cognitive function,quality of life,serum indicators,and adverse reactions of the two groups were compared.Results In the total effective rate of treatment,in comparision of the control group(80.88%),the study group(95.59%) was higher(P < 0.05).After 3 months of treatment,the scores of MoCA in both groups were increased(P < 0.05),and in comparision of the control group,the scores in the study group were higher(P < 0.05).After treatment,the scores of QOLIE-31 in both groups were improved(P < 0.05),and in comparision of the control group,the study group was higher(P < 0.05).After treatment,the levels of NPY and GFAP in both groups were decreased(P < 0.05),and in comparision of the control group,the levels in the study group were lower(P < 0.05).In the incidence of adverse reactions,in comparision of the control group(20.59%),the study group(4.41%) was lower(P < 0.05).Conclusion CBZ treatment for newly diagnosed partial epilepsy can improve clinical efficacy,enhance cognitive function,improve quality of life,improve serum indicators and reduce adverse reactions.